Patents by Inventor Tannin A. Schmidt
Tannin A. Schmidt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160304572Abstract: Disclosed are new recombinant isoforms of human-like lubricin or PRG4 glycoprotein having outstanding lubrication properties and a novel glycosylation pattern, and methods for their manufacture at high levels enabling commercial production.Type: ApplicationFiled: October 22, 2014Publication date: October 20, 2016Inventors: Tannin A. Schmidt, Gregory D. Jay
-
Patent number: 9421241Abstract: Provided herein are ophthalmically acceptable pharmaceutical compositions comprising PRG4 or lubricant fragments and a PRG4 inducing compound. The PRG4 inducing compound in the pharmaceutical composition of the present invention upregulates PRG4 expression and localization in the ocular surface for efficient surface boundary lubrication. In some instances, pharmaceutical compositions described herein are utilized for treating ophthalmic conditions, e.g., ocular boundary deficiency and symptoms associated therewith.Type: GrantFiled: August 20, 2015Date of Patent: August 23, 2016Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SCHEPENS EYE RESEARCH INSTITUTEInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Publication number: 20160235809Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.Type: ApplicationFiled: April 6, 2016Publication date: August 18, 2016Inventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Patent number: 9393285Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.Type: GrantFiled: November 5, 2010Date of Patent: July 19, 2016Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SCHEPENS EYE RESEARCH INSTITUTEInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Publication number: 20160101149Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes discomfort at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, or a lubricating fragment thereof, suspended in an ophthalmically acceptable vehicle. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.Type: ApplicationFiled: December 18, 2015Publication date: April 14, 2016Inventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Patent number: 9248161Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.Type: GrantFiled: May 8, 2014Date of Patent: February 2, 2016Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SCHEPENS EYE RESEARCH INSTITUTEInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Publication number: 20160015780Abstract: Provided herein are ophthalmically acceptable pharmaceutical compositions comprising PRG4 or lubricant fragments and a PRG4 inducing compound. The PRG4 inducing compound in the pharmaceutical composition of the present invention upregulates PRG4 expression and localization in the ocular surface for efficient surface boundary lubrication. In some instances, pharmaceutical compositions described herein are utilized for treating ophthalmic conditions, e.g., ocular boundary deficiency and symptoms associated therewith.Type: ApplicationFiled: August 20, 2015Publication date: January 21, 2016Inventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Patent number: 9138457Abstract: Provided herein are ophthalmically acceptable pharmaceutical compositions comprising a PRG4 inducing compound in combination with PRG4 (including a lubricant fragments, homologs, or isoforms thereof), and methods of using the same. The PRG4 inducing compound in the pharmaceutical composition of the present invention upregulates PRG4 expression and localization in the ocular surface for efficient surface boundary lubrication. In some instances, pharmaceutical compositions described herein are utilized for treating ophthalmic conditions, e.g., ocular boundary deficiency and symptoms associated therewith.Type: GrantFiled: November 5, 2010Date of Patent: September 22, 2015Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SCHEPENS EYE RESEARCH INSTITUTEInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Patent number: 8945604Abstract: The present invention provides an ophthalmic device, and method of use thereof, for an individual wearing an ophthalmic lens to increase ocular surface boundary lubrication. The invention device comprises an ophthalmic lens and a sacrificial mechanism disposed on the ophthalmic lens, wherein the sacrificial mechanism comprises a plurality of surface bound receptors, such as PRG4, hyaluronic acid, and DNA aptamers, that reversibly bound to a lubricating composition comprising a gel forming agent, a surfactant, or a combination thereof, effectively inhibiting or preventing protein and lipid adsorption on the surface of the lens, and mitigate shear stress and reduce the friction between the lens and the ocular surface of the individual in need.Type: GrantFiled: September 20, 2013Date of Patent: February 3, 2015Assignees: The Regents of the University of California, Schepens Eye Research InstituteInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Publication number: 20140296159Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.Type: ApplicationFiled: May 8, 2014Publication date: October 2, 2014Inventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Publication number: 20140099343Abstract: The present invention provides an ophthalmic device, and method of use thereof, for an individual wearing an ophthalmic lens to increase ocular surface boundary lubrication. The invention device comprises an ophthalmic lens and a sacrificial mechanism disposed on the ophthalmic lens, wherein the sacrificial mechanism comprises a plurality of surface bound receptors, such as PRG4, hyaluronic acid, and DNA aptamers, that reversibly bound to a lubricating composition comprising a gel forming agent, a surfactant, or a combination thereof, effectively inhibiting or preventing protein and lipid adsorption on the surface of the lens, and mitigate shear stress and reduce the friction between the lens and the ocular surface of the individual in need.Type: ApplicationFiled: September 20, 2013Publication date: April 10, 2014Applicants: Schepens Eye Research Institute, The Regents of the University of CaliforniaInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Patent number: 8563028Abstract: The present invention provides an ophthalmic device, and method of use thereof, for an individual wearing an ophthalmic lens to increase ocular surface boundary lubrication. The invention device comprises an ophthalmic lens and a sacrificial mechanism disposed on the ophthalmic lens, wherein the sacrificial mechanism comprises a plurality of surface bound receptors, such as PRG4, hyaluronic acid, and DNA aptamers, that reversibly bound to a lubricating composition comprising a gel forming agent, a surfactant, or a combination thereof, effectively inhibiting or preventing protein and lipid adsorption on the surface of the lens, and mitigate shear stress and reduce the friction between the lens and the ocular surface of the individual in need.Type: GrantFiled: November 5, 2010Date of Patent: October 22, 2013Assignees: The Regents of the University of California, Schepens Eye Research InstituteInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Patent number: 8551467Abstract: An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents.Type: GrantFiled: July 2, 2012Date of Patent: October 8, 2013Assignees: The Regents of the University of California, Schepens Eye Research InstituteInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Patent number: 8506944Abstract: An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents.Type: GrantFiled: October 23, 2009Date of Patent: August 13, 2013Assignees: The Regents of the University of California, Schepens Eye Research InstituteInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Publication number: 20120321611Abstract: An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents.Type: ApplicationFiled: July 2, 2012Publication date: December 20, 2012Applicants: SCHEPENS EYE RESEARCH INSTITUTE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Publication number: 20120134925Abstract: The present invention relates to the uses of the protein PRG4 and therapeutic modulation thereof. In particular, the present invention relates compositions and methods utilizing PRG4 and therapeutic modulation thereof, including, use as a surgical lubricant, use in a treatment for prevention or reduction of post-surgical adhesions, use in a treatment for oral ulcerations, use as an athletic lubricating patch, use as a dermal filler, use in a treatment for dry mouth, use in a drug delivery method or composition, and use in nursing lubrication.Type: ApplicationFiled: May 24, 2010Publication date: May 31, 2012Inventors: Benjamin Sullivan, Tannin Schmidt, Edward R. Truitt, Nicole Barbara Justis Truitt, David Sullivan
-
Publication number: 20110142908Abstract: The present invention provides an ophthalmic device, and method of use thereof, for an individual wearing an ophthalmic lens to increase ocular surface boundary lubrication. The invention device comprises an ophthalmic lens and a sacrificial mechanism disposed on the ophthalmic lens, wherein the sacrificial mechanism comprises a plurality of surface bound receptors, such as PRG4, hyaluronic acid, and DNA aptamers, that reversibly bound to a lubricating composition comprising a gel forming agent, a surfactant, or a combination thereof, effectively inhibiting or preventing protein and lipid adsorption on the surface of the lens, and mitigate shear stress and reduce the friction between the lens and the ocular surface of the individual in need.Type: ApplicationFiled: November 5, 2010Publication date: June 16, 2011Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SCHEPENS EYE RESEARCH INSTITUTEInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Publication number: 20110070222Abstract: Provided herein are ophthalmically acceptable pharmaceutical compositions comprising a PRG4 inducing compound in combination with PRG4 (including a lubricant fragments, homologs, or isoforms thereof), and methods of using the same. The PRG4 inducing compound in the pharmaceutical composition of the present invention upregulates PRG4 expression and localization in the ocular surface for efficient surface boundary lubrication. In some instances, pharmaceutical compositions described herein are utilized for treating ophthalmic conditions, e.g., ocular boundary deficiency and symptoms associated therewith.Type: ApplicationFiled: November 5, 2010Publication date: March 24, 2011Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SCHEPENS EYE RESEARCH INSTITUTEInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Publication number: 20110059902Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.Type: ApplicationFiled: November 5, 2010Publication date: March 10, 2011Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SCHEPENS EYE RESEARCH INSTITUTEInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Publication number: 20100092452Abstract: An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents.Type: ApplicationFiled: October 23, 2009Publication date: April 15, 2010Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SCHEPENS EYE RESEARCH INSTITUTEInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan